XML 71 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Fair Value Measurements (Tables)
 6 Months Ended
Jun. 29, 2024
Fair Value Disclosures [Abstract]  
Fair Value, Assets Measured on Recurring and Nonrecurring Basis
The table below summarizes the valuation of our financial instruments carried at fair value by the applicable pricing categories (in millions):
June 29, 2024December 31, 2023
Measured at fair value on a recurring basis:Level 1Level 2Level 3Level 1Level 2Level 3
Assets:
Investment securities$— $— $— $0.1 $— $— 
Foreign currency forward contracts— 2.2 — — 0.6 — 
Cross-currency swap— 3.3 — — — — 
Interest rate swap agreements— 14.9 — — 30.5 — 
Total assets$— $20.4 $— $0.1 $31.1 $— 
Liabilities:
Cross-currency swap$— $77.5 $— $— $172.0 $— 
Foreign currency forward contracts— 2.8 — — 2.7 — 
Interest rate swap agreements— 11.1 — — 11.7 — 
Total liabilities$— $91.4 $— $— $186.4 $— 
Measured at fair value on a non-recurring basis:
Assets:
Goodwill(1)
$— $— $93.1 $— $— $118.9 
Assets held for sale, net(2)
$— $— $147.7 $— $— $— 
Total assets held for sale, net$— $— $240.8 $— $— $118.9 
(1) During the year ended December 31, 2023, goodwill within the Rare Diseases Business with a carrying value of $208.9 million was written down to a fair value of $118.9 million. During the six months ended June 29, 2024, goodwill within the Rare Diseases Business was written down to a fair value of $93.1 million.
(2) We measured the net assets held for sale for impairment purposes and recorded a total impairment of $12.0 million, resulting in a net asset held for sale balance of $147.7 million (refer to Note 3).
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments
Our fixed rate long-term debt consisted of the following (in millions):
June 29, 2024December 31, 2023
Public BondsLevel 1Level 1
Carrying value (excluding discount)$2,244.4 $2,244.4 
Fair value$2,080.0 $2,062.2